COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00030186
Recruitment Status : Completed
First Posted : February 8, 2002
Last Update Posted : August 23, 2012
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Cephalon )

Brief Summary:
The purpose of this study is to determine the response rate of patients with refractory, relapsed or poor risk AML expressing FLT-3 activating mutations, when administered CEP-701 at a dosage of 60 mg 2 times a day.

Condition or disease Intervention/treatment Phase
Leukemia, Myeloid Drug: CEP-701 60mg Drug: Cep-701 80mg Drug: Cep-701 40mg Phase 2

Detailed Description:
This is an open-label study of CEP-701 in patients with refractory, relapsed, or poor risk AML expressing FLT-3 activating mutations. Patients who meet eligibility criteria will be enrolled at a dosage of 60 mg orally 2 times a day for 28 days (1 cycle). Upon completion of cycle 1, the dosage may be increased to 80mg 2 times a day or decreased to 40 mg 2 times a day, dependent upon response to 60 mg dosage.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 37 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Study of CEP-701 in Patients With Refractory, Relapsed, or Poor Risk Acute Myeloid Leukemia Expressing FLT-3 Activating Mutations
Study Start Date : January 2002
Actual Primary Completion Date : February 2003
Actual Study Completion Date : February 2003

Arm Intervention/treatment
Experimental: Cycle 1
Drug: CEP-701 60mg
60mg orally 2 times a day for 28 days

Experimental: Cycle 2
80mg dependent upon response to Cycle 1
Drug: Cep-701 80mg
80mg 2 times a day, dependent upon response to cycle 1

Experimental: Cycle 2b
40mg dependent upon response to Cycle 1
Drug: Cep-701 40mg
40mg 2 times a day, dependent upon response to cycle 1

Primary Outcome Measures :
  1. Blood Samples and/or bone marrow assessments for complete remission (CR), complete tumor clearance (CTC), or hematologic response (HR) from bone marrow [ Time Frame: 56 days ]
    Response rate of patients with refactory, relapsed, or poor risk acute myeloid leukemia (AML) expressing Fms-like tyrosine kinase 3 (FLT-3) activating mutations. CR is defined as presence of less than 5% myeloblasts in bone marrow with normalized peripheral blood cell counts. HR is defined as a 50% or more decrease in the absolute number of peripheral blast count or at least a 50% reduction in bone marrow blasts.

Secondary Outcome Measures :
  1. Number of days to response [ Time Frame: 56 Days ]
    Response as defined by CR, CTC, or HR.

  2. Number of days to disease progression [ Time Frame: 56 Days ]
    Response as defined by CR, CTC, or HR.

  3. Levels of FLT-3 phosphorylation inhibition in vivo [ Time Frame: 56 Days ]
    The degree of inhibition of FLT-3 autophosphorylation measured in ex vivo bioassay plasma samples

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • patient must have confirmed diagnosis of refractory or relapsed AML that expresses a FLT-3 mutation
  • patient must have life expectancy of more than 2 months
  • patient must be fully recovered from reversible side effects of previous therapy for cancer


  • total bilirubin, ALT or AST greater than 2 times upper limit of normal
  • patient <65 years of age with estimated creatinine clearance less than 60 mL/min; patient >65 years of age with serum creatinine > 1.5 times the upper limit of normal (ULN)
  • received any investigational drug within past 4 weeks
  • GI disturbance/malabsorption that may affect absorption of CEP-701
  • HIV positive
  • received NSAID within prior 14 days
  • has active infection

Layout table for additonal information
Responsible Party: Cephalon Identifier: NCT00030186    
Other Study ID Numbers: C0701a/202/ON/US
First Posted: February 8, 2002    Key Record Dates
Last Update Posted: August 23, 2012
Last Verified: August 2012
Keywords provided by Teva Pharmaceutical Industries ( Cephalon ):
FLT-3 mutation
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type